Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Numeral Limited (XII.JO)
Phoenix, MU
Headquartered in Phoenix, Mauritius, Numeral Limited operates as an investment holding entity with diverse interests across the biotech, health and pharmaceutical, and financial sectors within the country. The company also provides an extensive array of ancillary services, including legal support, human resources, technology assistance, financial consulting, corporate finance, marketing, and business acquisition solutions. Established in 2010, the firm adopted its current designation, Numeral Limited, in December 2023, having formerly been known as Go Life International Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +9,614.29% | -15.00% | +70.00% | +70.00% | +240.00% | +33,900.00% | +16,900.00% | +518.18% | +518.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Pharmaceuticals: +7.8%+1,939.2% ★ Q4'25: +176.0% (vs Q4'24)
-
EPS growth Medical - Pharmaceuticals: +20.2%+5,532.2% ★ Q4'25: -44.4% (vs Q4'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-9.5% Q4'25: -86.3% (vs Q4'24)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+27.9% ★ Q4'25: +16.7% (vs Q4'24)
-
ROIC Medical - Pharmaceuticals: +6.1%+19.4% ★ Q4'25: +14.7% (vs Q4'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×4.65× Q4'25: 9.93× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gerhad Christiaan Jacobus Naudé | Group Advisor | 458.9K | male |
| Mohamed Yusuf Sooklall | Independent Non-Executive Chairman | 295.0K | male |
| Marthinus Johannes Wolmarans | Chief Financial Officer | 229.5K | male |
| Neville Graham | Executive Director | — | male |
| David Van Niekerk | Executive Director | — | male |
| Patrick David Wysoczanski | Chief Executive Officer | — | male |
| J. J. Rabie | Company Secretary | — | male |
| Jacobus Botma | Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XII.JO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
